FGF23 in Acute and Chronic Illness

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2015 Oct 23

PMID 26491212

Citations 17

Authors

Christian Schnedl

Astrid Fahrleitner-Pammer

Peter Pietschmann

Karin Amrein

Affiliations

Soon will be listed here.

Abstract

FGF23 is a bone-derived phosphaturic hormone that may become a useful biomarker for the identification of high-risk patients in chronic but also acute disease. It rises early in chronic kidney disease and is strongly and independently associated with excess morbidity and mortality. Emerging data suggest that FGF23 is also elevated in different scenarios of acute illness. In this review, we give an overview on the role of this interesting disease marker and potential and proven interventional strategies and discuss a blueprint for future research.

Citing Articles

Non-Classical Effects of FGF23: Molecular and Clinical Features.

Martinez-Heredia L, Canelo-Moreno J, Garcia-Fontana B, Munoz-Torres M Int J Mol Sci. 2024; 25(9).

PMID: 38732094 PMC: 11084844. DOI: 10.3390/ijms25094875.

Acute liver injury induces expression of FGF23 in hepatocytes via orphan nuclear receptor ERRγ signaling.

Jung Y, Kim Y, Radhakrishnan K, Noh J, Choi J, Kim H Genes Dis. 2023; 10(3):679-682.

PMID: 37396546 PMC: 10308101. DOI: 10.1016/j.gendis.2022.06.003.

Raised FGF23 Correlates to Increased Mortality in Critical Illness, Independent of Vitamin D.

Thein O, Ali N, Mahida R, Dancer R, Ostermann M, Amrein K Biology (Basel). 2023; 12(2).

PMID: 36829583 PMC: 9953634. DOI: 10.3390/biology12020309.

Critical illness and bone metabolism: where are we now and what is next?.

Cai Y, Kang F, Wang X Eur J Med Res. 2022; 27(1):177.

PMID: 36104724 PMC: 9472372. DOI: 10.1186/s40001-022-00805-w.

Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.

Trombetti A, Al-Daghri N, Brandi M, Cannata-Andia J, Cavalier E, Chandran M Nat Rev Endocrinol. 2022; 18(6):366-384.

PMID: 35484227 DOI: 10.1038/s41574-022-00662-x.

References

Ferrari S, Bonjour J, Rizzoli R . Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2004; 90(3):1519-24. DOI: 10.1210/jc.2004-1039. View

Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M . Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2011; 27(2):784-90. DOI: 10.1093/ndt/gfr384. View

Leaf D, Waikar S, Wolf M, Cremers S, Bhan I, Stern L . Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. Clin Endocrinol (Oxf). 2013; 79(4):491-8. PMC: 3686895. DOI: 10.1111/cen.12172. View

Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse H . Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004; 145(7):3087-94. DOI: 10.1210/en.2003-1768. View

Leaf D, Wolf M, Waikar S, Chase H, Christov M, Cremers S . FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol. 2012; 7(8):1217-23. PMC: 3408118. DOI: 10.2215/CJN.00550112. View

Uzum A, Salman S, Telci A, Boztepe H, Tanakol R, Alagol F . Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur J Endocrinol. 2010; 163(5):825-31. DOI: 10.1530/EJE-10-0591. View

Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C . Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2007; 46(12):1852-7. DOI: 10.1093/rheumatology/kem240. View

Bacchetta J, Sea J, Chun R, Lisse T, Wesseling-Perry K, Gales B . Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res. 2012; 28(1):46-55. PMC: 3511915. DOI: 10.1002/jbmr.1740. View

Sarnak M, Jaber B . Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000; 58(4):1758-64. DOI: 10.1111/j.1523-1755.2000.00337.x. View

10.

Rousseau A, Damas P, Ledoux D, Cavalier E . Effect of cholecalciferol recommended daily allowances on vitamin D status and fibroblast growth factor-23: an observational study in acute burn patients. Burns. 2014; 40(5):865-70. DOI: 10.1016/j.burns.2013.11.015. View

11.

Dallas S, Prideaux M, Bonewald L . The osteocyte: an endocrine cell ... and more. Endocr Rev. 2013; 34(5):658-90. PMC: 3785641. DOI: 10.1210/er.2012-1026. View

12.

Rodriguez M, Lopez I, Munoz J, Aguilera-Tejero E, Almaden Y . FGF23 and mineral metabolism, implications in CKD-MBD. Nefrologia. 2012; 32(3):275-8. DOI: 10.3265/Nefrologia.pre2012.Mar.11415. View

13.

Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A . Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis. 2004; 44(3):481-7. View

14.

Kendrick J, Cheung A, Kaufman J, Greene T, Roberts W, Smits G . FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011; 22(10):1913-22. PMC: 3187186. DOI: 10.1681/ASN.2010121224. View

15.

Isakova T, Xie H, Yang W, Xie D, Anderson A, Scialla J . Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23):2432-9. PMC: 3124770. DOI: 10.1001/jama.2011.826. View

16.

Klein G, Herndon D, Le P, Andersen C, Benjamin D, Rosen C . The effect of burn on serum concentrations of sclerostin and FGF23. Burns. 2015; 41(7):1532-5. PMC: 4618193. DOI: 10.1016/j.burns.2015.04.001. View

17.

Zhang M, Hsu R, Hsu C, Kordesch K, Nicasio E, Cortez A . FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series study. Ann Intensive Care. 2011; 1(1):21. PMC: 3224491. DOI: 10.1186/2110-5820-1-21. View

18.

Mirza M, Alsio J, Hammarstedt A, Erben R, Michaelsson K, Tivesten A . Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol. 2010; 31(1):219-27. DOI: 10.1161/ATVBAHA.110.214619. View

19.

Christov M, Waikar S, Pereira R, Havasi A, Leaf D, Goltzman D . Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int. 2013; 84(4):776-85. PMC: 3766419. DOI: 10.1038/ki.2013.150. View

20.

Stubbs J, Liu S, Tang W, Zhou J, Wang Y, Yao X . Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007; 18(7):2116-24. DOI: 10.1681/ASN.2006121385. View